U.S. markets open in 34 minutes

Lonza Group Ltd (LZAGY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
59.39+1.26 (+2.16%)
At close: 3:56PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close58.13
Bid0.00 x 0
Ask0.00 x 0
Day's Range58.89 - 59.64
52 Week Range40.02 - 69.07
Avg. Volume89,714
Market Cap44.073B
Beta (5Y Monthly)0.43
PE Ratio (TTM)47.22
EPS (TTM)1.26
Earnings DateN/A
Forward Dividend & Yield0.14 (0.24%)
Ex-Dividend DateMay 01, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    UPDATE 1-Spain's Rovi to make ingredients for Moderna's COVID-19 vaccine

    Spanish pharmaceuticals company Rovi announced on Monday that it will start making the active ingredients for Moderna's COVID-19 vaccine. Rovi will have capacity to supply the active agents for up to 100 million vaccine doses a year at its plant in Granada via a new production line. This would be the first European drug ingredients production site for Moderna outside of Switzerland, where Lonza has one large commercial production line now manufacturing drug substances and another two commercial lines nearing completion.

  • UPDATE 1-Lonza gets licence to make ingredients for Moderna vaccine

    UPDATE 1-Lonza gets licence to make ingredients for Moderna vaccine

    Swiss contract drug manufacturer Lonza received a key licence from Switzerland to produce ingredients for Moderna's COVID-19 vaccine, regulator Swissmedic said on Monday, a boost for a global inoculation program that has hit some snags. The licence, for Lonza's new $70 million production line in Visp, Switzerland, dedicated to make ingredients for the Moderna vaccine, will help boost the U.S.-based company's deliveries to Europe, Canada and other nations outside the United States.

  • Benzinga

    Altimmune Shares Are Trading Higher On Expanded Manufacturing Pact With Lonza

    Altimmune Inc (NASDAQ: ALT) has expanded its previously-announced manufacturing collaboration with Lonza Group (OTCMKT: LZAGY) for AdCOVID, its single-dose intranasal COVID-19 vaccine candidate. Under the expansion, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, at its facility near Houston, Texas. In December, the FDA issued a clinical hold on Altimmune's investigational New Drug application for AdCOVID. The agency requested certain protocol modifications and the submission of additional chemistry, manufacturing, and controls data. The recently commenced Phase 1 study with data readout is expected in the second quarter of 2021. Price Action: ALT shares gained 19.7% at $20.20 in the premarket trading on the last check Friday. See more from BenzingaClick here for options trades from BenzingaSanofi, Translate Bio Initiate Human Trial Of mRNA COVID-19 Vaccine CandidatePfizer To Contemplate Additional Production Sites After Pandemic-Related Pressure Is Over: Reuters© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.